YSL Beauté sales
This article was originally published in The Rose Sheet
Executive Summary
Gucci beauty division sales in the first quarter (ended April 30) increased 2.4% to $158.7 mil. (€1=$1.13) on constant currency basis, but declined 1.2% on a reported basis, luxury goods manufacturer announces July 2. Yves Saint Laurent brand sales increased 3.5% on a constant currency basis driven by 3.1% growth from fragrances and 5.4% growth in makeup, Gucci adds. The division benefited from launches of fragrances including Alexander McQueen Kingdom, Zegna Essenza di Zegna during the period, but marketing expenses and start up costs contributed to an operating loss for the division in the quarter. Operating loss before goodwill and trademark amortization was $7.9 mil. compared with profit of $3.4 mil. in the year ago period...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.